Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 773

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Surgical Treatment of Neuroendocrine Metastases to the Liver: : a plea for resection to increase survival

Sarmiento, Juan M, Heywood, Glenroy, Rubin, Joseph, Ilstrup, Duane M, Nagorney, David M, Que, Florencia G·2003·Journal of the American College of Surgeons
DOI 10.1016/s1072-7515(03)00230-8
Open this paper in CoChat — free account

Abstract

BACKGROUND: Hepatic metastases from neuroendocrine tumors have a protracted natural history and are associated with endocrinopathies. Resection is indicated for symptom control. Previous reports have suggested improvement in survival for patients undergoing debulking procedures. STUDY DESIGN: The records of all consecutive patients undergoing resection of hepatic metastases from neuroendocrine tumors between 1977 and 1998 were reviewed. Tumors were classified according to histology, endocrine activity, and primary location. Patients lost to followup before 1 year were excluded. Followups were based on outpatient evaluations and were updated by correspondence. The Kaplan-Meier method was used to generate survival and recurrence curves, and the log-rank test was used for comparison. RESULTS: A total of 170 patients fulfilled the inclusion criteria, of whom 73 were men. Mean age (+/-SD) was 57 (+/-11.5) years. Carcinoid (n = 120) and nonfunctioning islet cell tumors (n = 18) predominated; the ileum (n = 85) and the pancreas (n = 52) were the most common primary sites. Major hepatectomy (one or more lobes) was performed in 91 patients (54%). The postoperative complication rate was 14%, and two patients died (1.2%). Operation controlled symptoms in 104 of 108 patients, but the recurrence rate at 5 years was 59%. Operation decreased 5-hydroxyindoleacetic acid levels considerably, and no patient experienced carcinoid heart disease postoperatively. Recurrence rate was 84% at 5 years. Overall survival was 61% and 35% at 5 and 10 years, respectively, with no difference between carcinoid and islet cell tumors. CONCLUSIONS: Hepatic resection for metastatic neuroendocrine tumors is safe and achieves symptom control in most patients. Debulking extends survival, although recurrence is expected. Hepatic resection is justified by its effects on survival and quality of life.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1072-7515(03)00230-8

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 773

Metadata

Authors
Sarmiento, J. M., Heywood, G., Rubin, J., Ilstrup, D. M., Nagorney, D. M., & Que, F. G.
Venue
Journal of the American College of Surgeons
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2003-07
Volume
197
Issue
1
Pages
29-37
ISSN
1072-7515 (ISSN-L)
DOI
10.1016/s1072-7515(03)00230-8
OpenAlex
W1982345319
Cited by
773
References
12
FWCI
15.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Surgical Treatment of Neuroendocrine Metastases to the Liver: : a plea for resection to increase survival. https://app.cochat.ai/papers/10.1016/s1072-7515(03)00230-8
The paper
Sarmiento, J. M., Heywood, G., Rubin, J., Ilstrup, D. M., Nagorney, D. M., & Que, F. G. (2003). Surgical Treatment of Neuroendocrine Metastases to the Liver: : a plea for resection to increase survival. Journal of the American College of Surgeons. https://doi.org/10.1016/s1072-7515(03)00230-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.